EPISODE · Jul 27, 2020 · 31 MIN
Moderna CEO Racing for a Vaccine; Harlem Children’s Zone’s National Covid Relief
from Squawk Pod · host CNBC
As coronavirus cases spike in hot spots across the country, biopharmaceutical companies race to find a vaccine. Moderna Therapeutics has secured an additional $472 million in government funding to develop its own vaccine candidate, which begins phase 3 human trials today. Moderna CEO Stéphane Bancel discusses the vaccine development and addresses concerns about his executive team’s lucrative and unscheduled stock sales over the past six months. The Harlem Children’s Zone is going national with its efforts to provide communities with holistic Covid-19 relief. President Geoffrey Canada and CEO Kwame Owusu-Kesse discuss the disproportionate effect the pandemic has had on Black communities, and share their approach to scaling relief efforts from NYC to six other cities across the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
As coronavirus cases spike in hot spots across the country, biopharmaceutical companies race to find a vaccine. Moderna Therapeutics has secured an additional $472 million in government funding to develop its own vaccine candidate, which begins phase 3 human trials today. Moderna CEO Stéphane Bancel discusses the vaccine development and addresses concerns about his executive team’s lucrative and unscheduled stock sales over the past six months. The Harlem Children’s Zone is going national with its efforts to provide communities with holistic Covid-19 relief. President Geoffrey Canada and CEO Kwame Owusu-Kesse discuss the disproportionate effect the pandemic has had on Black communities, and share their approach to scaling relief efforts from NYC to six other cities across the US.
NOW PLAYING
Moderna CEO Racing for a Vaccine; Harlem Children’s Zone’s National Covid Relief
No transcript for this episode yet
Similar Episodes
Mar 14, 2026 ·23m
Mar 11, 2026 ·16m
Feb 28, 2026 ·14m